Pfizer Aktie
| 24,95USD | -0,16USD | -0,64% |
WKN: 852009 / ISIN: US7170811035
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,96 |
| The Vanguard Group, Inc. | 8,94 |
| Vanguard Group, Inc. (Subfiler) | 8,65 |
| State Street Corp. | 5,13 |
| SSgA Funds Management, Inc. | 5,08 |
| Vanguard Total Stock Market ETF | 3,17 |
| Wellington Management Co. LLP (Wellington Breakout) | 2,74 |
| BlackRock Fund Advisors | 2,65 |
| Vanguard 500 Index Fund | 2,62 |
| Charles Schwab Investment Management, Inc. | 2,30 |
| BlackRock Institutional Trust Co. NA | 2,21 |
| Geode Capital Management LLC | 2,08 |
| Schwab US Dividend Equity ETF | 1,55 |
| Norges Bank (13F) | 1,48 |
| Massachusetts Financial Services Co. | 1,26 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 88 300 | 78 500 | 79 000 | 83 000 | 88 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,59 | 0,53 | 1,03 | 1,21 | 0,66 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 32 803 | 35 067 | 59 693 | 51 259 | 43 333 |
| Summe Anlagevermögen | 134 686 | 119 162 | 121 783 | 145 946 | 183 168 |
| Summe Aktiva | 167 489 | 154 229 | 181 476 | 197 205 | 226 501 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 53 474 | 41 271 | 41 395 | 39 046 | 75 041 |
| Summe Fremdkapital | 104 044 | 90 756 | 104 013 | 101 288 | 137 213 |
| Summe Eigenkapital | 63 445 | 63 473 | 77 463 | 95 917 | 89 288 |
| Summe Passiva | 167 489 | 154 229 | 181 476 | 197 205 | 226 501 |
Adresse
| 66 Hudson Boulevard East, 10001-2192 New York | |
| Telefon | +1 (212) 733-2323 |
| Internet | http://www.pfizer.com |
Management
|
Aamir Malik
Chief Commercial Officer-US & Executive VP |
|
Aida Habtezion
Chief Medical Officer & Head-Worldwide Medical |
|
Albert Bourla
Chairman & Chief Executive Officer |
|
Alexandre de Germay
Chief International Commercial Officer & EVP |
|
Annaliesa Anderson
SVP, Head-Vaccine Research & Development |
|
Barbara J. Dalton
Vice President-Worldwide Business Development |
|
Berta Rodriguez-Hervas
Chief Artificial Intelligence & Analytics Officer |
|
Bryan Supran
Senior Vice President & Deputy General Counsel |
|
Chris Boshoff
Chief Oncology Officer & Executive Vice President |
|
Christopher J. Stevo
Chief Investor Relations Officer & Senior VP |
|
Cyrus Russi Taraporevala
Non-Executive Director |
|
Dan R. Littman
Independent Director |
|
David M. Denton
Chief Financial Officer & Executive Vice President |
|
Denis Patrick
Executive Director & Vice President-WRDM |
|
Douglas M. Lankler
Executive Vice President & General Counsel |
|
François-Maurice Garnier
International General Counsel |
|
Gordon Loh
Senior Vice President-Corporate Audit |
|
Helen H. Hobbs
Independent Director |
|
James C. Smith
Independent Director |
|
James Quincey
Independent Director |
|
Jeff Settleman
Co-Chief Scientific Officer |
|
Jennifer B. Damico
Senior Vice President & Controller |
|
John DeYoung
Vice President-Worldwide Business Development |
|
Joseph J. Echevarria
Independent Director |
|
Lidia L. Fonseca
Executive VP, Chief Technology & Digital Officer |
|
Luis Jodar
Chief Medical Officer-Vaccines & Senior VP |
|
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP |
|
Maria Rivas
Chief Medical Affairs Officer |
|
Markus Green
Vice President & Assistant General Counsel |
|
Michael Mcdermott
Chief Global Supply Officer & Executive VP |
|
Mikael Dolsten
Co-Chief Scientific Officer & President-Research |
|
Mortimer Joseph Buckley
Director |
|
Patrice Ettinger
Chief Privacy Offucer |
|
Payal Sahni Becher
Chief People Experience Officer & Executive VP |
|
Rady A. Johnson
EVP, Chief Compliance, Quality & Risk Officer |
|
Roger D. Dansey
Chief Development Officer-Oncology |
|
Ronald Edward Blaylock
Independent Director |
|
Sally Susman
Chief Corporate Affairs Officer & Executive VP |
|
Scott Gottlieb
Independent Director |
|
Shantanu Narayen
Lead Independent Director |
|
Suneet Varma
President-US Oncology Business Unit |
|
Susan D. Desmond-Hellmann
Independent Director |
|
Susan J. Hockfield
Independent Director |
|
Susan Rienow
Global Chief Marketing Officer |
|
Suzanne Nora Johnson
Independent Director |
|
William C. Sessa
SVP &Chief Scientific Officer-Internal Medicine |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
